作者: Dorte X Gram , Jens J Holst , Arpad Szallasi , None
DOI: 10.1016/J.MOLMED.2017.09.005
关键词:
摘要: With an estimated 422 million affected patients worldwide in 2016, type 2 diabetes (T2D) has reached pandemic proportions and represents a major unmet medical need. T2D is polygenic disease with chronic, low-grade inflammatory component. Second-generation transient receptor potential vanilloid-1 (TRPV1) antagonists are potent anti-inflammatory agents proven clinical safety. In rodent models of T2D, TRPV1 blockade was shown to halt progression improve glucose metabolism. Thus, we propose that merit further study as novel therapeutic approaches potentially treat its comorbidities.